GeoVax Labs, Inc. — Q2 2015 Form 10-Q
Reporting period: Quarter and six months ended June 30, 2015; financial statements are unaudited. GeoVax is a clinical-stage biotechnology company developing vaccines for HIV, Ebola and Marburg. Revenue reported was NIH grant revenue; the company had no approved products or commercialization capabilities.
Financial performance and liquidity
| Metric | Q2 2015 | Q2 2014 | Six months 2015 | Six months 2014 |
|---|---|---|---|---|
| Grant revenue | $71,474 | $180,441 | $174,898 | $337,781 |
| Research and development expense | $384,653 | $516,202 | $788,282 | $919,062 |
| General and administrative expense | $364,889 | $344,862 | $766,330 | $716,664 |
| Net loss | $676,203 | $679,537 | $1,376,657 | $1,295,455 |
| Net loss per share | $0.02 | $0.03 | $0.04 | $0.05 |
- Six-month operating expenses were $1,554,612 versus $1,635,726 a year earlier. Operating loss was $1,379,714 versus $1,297,945.
- Cash and cash equivalents were $2,475,726 at June 30, 2015, up from $1,101,651 at December 31, 2014. Working capital was $2,373,831, up from $1,038,472.
- Six-month operating cash use was $1,289,884; investing cash use was $15,850; financing provided $2,679,809, principally from the February preferred-stock financing. Ending cash was $2,475,726.
- Current liabilities were $181,089. The company reported no long-term debt or committed credit lines. Cash runway and liquidity remain dependent on grants and additional funding.
- Margins are not a meaningful indicator here: the company is development-stage, has no product revenue, and grant revenue is recognized as related costs are incurred.
Material changes versus comparable periods
- Q2 net loss was nearly unchanged year over year; the six-month net loss increased by about $81,000. Grant revenue fell for both the quarter and half-year, reflecting lower grant-supported spending.
- Six-month R&D expense decreased about $131,000, while G&A expense increased about $50,000. Operating cash use increased from $1,130,895 to $1,289,884.
- In February, GeoVax raised $3.0 million gross, approximately $2.7 million net, by issuing Series C convertible preferred stock. The conversion price was adjusted to $0.142 per share in April, and associated warrant prices were also adjusted.
- At June 30, common shares outstanding were 31,950,813. The filing lists 79,052,160 shares reserved for potential issuance, including preferred-stock conversions, warrants and equity plans; actual dilution depends on conversions, vesting and warrant exercises.
Outlook, risks and unusual items
- Management expected existing cash and grant commitments to fund planned operations through the first quarter of 2016, but said additional funds would be required beyond then. The filing identifies substantial doubt about the company’s ability to continue as a going concern beyond that period; management cited its funding history but cautioned that new funding may not be available on favorable terms or at all.
- Management was pursuing government grants, NIH clinical-trial support and philanthropic support, and could seek equity financing or warrant exercises. Failure to raise capital could force delays, reductions or discontinuation of programs.
- Planned work included an NIH-supported Phase 1 HIV “protein boost” trial expected to begin in late 2015; GeoVax was also seeking support to advance its HIV vaccine toward a Phase 2b efficacy trial. Ebola/Marburg animal studies were underway, with human trials anticipated in late 2016 or early 2017, subject to development and funding.
- GeoVax expected R&D costs to rise as programs advance. Vaccine efficacy, safety, clinical timelines, regulatory approval and future financing are uncertain; the company could not estimate when, or whether, product-related cash inflows might begin.
- Remaining approved grant funds were $353,652 at June 30, 2015. Lease and other firm purchase commitments totaled approximately $188,000; about $115,300 of vendor and subcontractor purchase commitments were unrecorded and expected to be due in 2015.
- The filing reported no legal proceedings and no material changes to previously disclosed risk factors. Management stated disclosure controls were effective and reported no material change in internal control over financial reporting during the quarter.
Important facts for investors to verify
- Whether new grants, clinical-trial support or other capital are secured in time to extend the stated cash runway beyond Q1 2016.
- Progress, funding and timing for the planned HIV trial and Ebola/Marburg preclinical program.
- Potential dilution and cash proceeds associated with Series C conversion terms and the substantial warrant pool, including the warrants’ exercise conditions and anti-dilution provisions.
- Actual cash burn, grant availability and spending relative to management’s runway estimate in subsequent filings.